CLINICAL TRIALS PROFILE FOR CEFTRIAXONE

505(b)(2) Clinical Trials for CEFTRIAXONE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00244777 ↗	Introduction of Hypo-osmolar ORS for Routine Use	Completed	United States Agency for International Development (USAID)	Phase 4	2002-12-01	The World Health Organization has very recently recommended the routine use of a hypo-osmolar ORS in the management of diarrhoeal diseases. This recommendation is based on the better efficacy of the hypo-osmolar ORS over the standard WHO ORS demonstrated in controlled clinical trials. The recommendation, however, also expressed the need for "careful monitoring to better assess risk, if any, of symptomatic hyponatraemia". There thus is a need for phase IV trials before the new solution is introduced into routine clinical practice to assess the risk in relatively large number of patient populations. The proposed study will be carried out at two different settings- at the urban settings of the Dhaka Hospital (60000 patients) and at the rural settings of the Matlab Hospital (15000 patients) of ICDDR,B. The hypo-osmolar rice or glucose-based ORS will be introduced as standard management of patients with diarrhoea . The hypo-osmolar ORS will contain 75 mmol /L of sodium instead of 90 mmol/L. Surveillance will be carried out to detect adverse events focusing on the occurrence of seizures or undue lethargy during hospitalization. Each episode of seizure or undue lethargy would be evaluated to determine if they are associated with abnormal levels of serum sodium or glucose, or fever. It has been estimated that about 3% (1,800) of patients initially admitted to the Short Stay Ward of the Dhaka Hospital, and 340 patients at the Matlab Hospital might require admission to the longer stay inpatient wards due to seizure or altered consciousness. Such patients would be thoroughly assessed including determination of their serum sodium and glucose, two common causes of seizures/altered consciousness, to determine if and to what extent they could be attributed to hyponatraemia.The results from this study would be used in planning and implementing the routine use of the new formulation of ORS at all Government, NGO and private health care facilities that treat diarrhoeal patients, in Bangladesh and in other countries.
New Formulation	NCT00244777 ↗	Introduction of Hypo-osmolar ORS for Routine Use	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 4	2002-12-01	The World Health Organization has very recently recommended the routine use of a hypo-osmolar ORS in the management of diarrhoeal diseases. This recommendation is based on the better efficacy of the hypo-osmolar ORS over the standard WHO ORS demonstrated in controlled clinical trials. The recommendation, however, also expressed the need for "careful monitoring to better assess risk, if any, of symptomatic hyponatraemia". There thus is a need for phase IV trials before the new solution is introduced into routine clinical practice to assess the risk in relatively large number of patient populations. The proposed study will be carried out at two different settings- at the urban settings of the Dhaka Hospital (60000 patients) and at the rural settings of the Matlab Hospital (15000 patients) of ICDDR,B. The hypo-osmolar rice or glucose-based ORS will be introduced as standard management of patients with diarrhoea . The hypo-osmolar ORS will contain 75 mmol /L of sodium instead of 90 mmol/L. Surveillance will be carried out to detect adverse events focusing on the occurrence of seizures or undue lethargy during hospitalization. Each episode of seizure or undue lethargy would be evaluated to determine if they are associated with abnormal levels of serum sodium or glucose, or fever. It has been estimated that about 3% (1,800) of patients initially admitted to the Short Stay Ward of the Dhaka Hospital, and 340 patients at the Matlab Hospital might require admission to the longer stay inpatient wards due to seizure or altered consciousness. Such patients would be thoroughly assessed including determination of their serum sodium and glucose, two common causes of seizures/altered consciousness, to determine if and to what extent they could be attributed to hyponatraemia.The results from this study would be used in planning and implementing the routine use of the new formulation of ORS at all Government, NGO and private health care facilities that treat diarrhoeal patients, in Bangladesh and in other countries.

All Clinical Trials for CEFTRIAXONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	Hoffmann-La Roche	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000938 ↗	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	Lyme disease is the most common tick-borne disease in the United States. It is caused by the spirochete Borrelia burgdorferi. It may exist in a chronic form and be the result of: 1) persistent infection by B. burgdorferi; 2) damage caused by the original infectious process; or 3) the presence of coinfection with another organism transmitted by Ixodes ticks. The purpose of this study is to determine the safety and effectiveness, in seronegative patients, of intensive antibiotic treatment in eliminating symptoms of Chronic Lyme Disease (CLD).
NCT00001101 ↗	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	Lyme disease is the most common tick-borne disease in the United States. It is caused by the spirochete Borrelia burgdorferi. It may exist in a chronic form and be the result of: 1) active infection by B. burgdorferi; 2) damage caused by the original infectious process; or 3) the presence of co-infection with another organism transmitted by Ixodes ticks. The purpose of this study is to determine the safety and effectiveness, for seropositive patients, of intensive antibiotic treatment in eliminating symptoms of Chronic Lyme Disease (CLD).
NCT00002052 ↗	Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients	Completed	University of Southern California	N/A	1969-12-31	To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.
NCT00004216 ↗	VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy	Completed	Vion Pharmaceuticals	Phase 1	1999-08-01	RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous therapy.
NCT00034736 ↗	A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2002-08-01	The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.

Clinical Trial Conditions for CEFTRIAXONE

Condition Name

Condition Name for CEFTRIAXONE
Intervention	Trials
Pneumonia	11
Sepsis	9
Gonorrhea	6
Surgical Site Infection	5

Condition MeSH

Condition MeSH for CEFTRIAXONE
Intervention	Trials
Infections	43
Pneumonia	35
Infection	34
Communicable Diseases	28

Clinical Trial Locations for CEFTRIAXONE

Trials by Country

Trials by Country for CEFTRIAXONE
Location	Trials
United States	245
France	35
Australia	32
Canada	26
Spain	26

Trials by US State

Trials by US State for CEFTRIAXONE
Location	Trials
Ohio	19
California	18
Texas	14
North Carolina	13
New York	13

Clinical Trial Progress for CEFTRIAXONE

Clinical Trial Phase

Clinical Trial Phase for CEFTRIAXONE
Clinical Trial Phase	Trials
PHASE4	8
PHASE3	4
PHASE2	1

Clinical Trial Status

Clinical Trial Status for CEFTRIAXONE
Clinical Trial Phase	Trials
Completed	97
RECRUITING	30
Unknown status	23

Clinical Trial Sponsors for CEFTRIAXONE

Sponsor Name

Sponsor Name for CEFTRIAXONE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	11
Forest Laboratories	8
Assistance Publique - Hôpitaux de Paris	7

Sponsor Type

Sponsor Type for CEFTRIAXONE
Sponsor	Trials
Other	242
Industry	62
NIH	16

Cephtriaxone (Ceftriaxone): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 25, 2026

What is ceftriaxone’s clinical-trial landscape?

Ceftriaxone is an established third-generation cephalosporin with a mature evidence base and broad global use. Current clinical development activity is dominated by (1) formulation work (especially pediatric and other optimized dosing formats), (2) new administration pathways (including infusion regimens and reconstitutions), and (3) comparative or non-inferiority studies versus other beta-lactams rather than first-in-class efficacy trials.

Key pattern in recent registries and publications

• Patient-population focus: pediatric dosing optimization, including neonates and infants; continued attention to pharmacokinetics and tolerability.
• Design pattern: comparative trials (non-inferiority or safety/PK endpoints) and practical clinical endpoints such as microbiological eradication rates.
• Regulatory driver: alignment with label refinements in specific geographies, including updated dosing guidance for pediatric use and infection subtypes.

Practical read-through for R&D planning

• The probability-weighted opportunity is highest in formulation, dosing convenience, and lifecycle extensions, not in brand-new antibacterial mechanism claims.
• For any new entrant, competitive differentiation typically requires either better pharmacokinetics in targeted populations or lower administration burden (less painful, faster reconstitution, fewer handling steps), because efficacy is already “de-risked” by existing standard-of-care positioning.

What clinical data matters most for market positioning?

For ceftriaxone, commercial uptake tracks closely to guideline inclusion and hospital formularies, which in turn depend on:

• Spectrum fit: Gram-negative coverage and established clinical utility across community-acquired and hospital-acquired settings.
• Administration and dosing convenience: once-daily regimens in many infections and widely standardized administration procedures.
• Safety profile in label populations: tolerability in pediatric and adult use, plus operational controls that hospitals already embed (dose adjustments, monitoring).

Core clinical evidence is longstanding, so new trials that move prescribing behavior typically must:

• Demonstrate non-inferiority against comparator beta-lactams, and/or
• Provide usable pediatric or administration advantages that shorten time-to-therapy or reduce dosing errors.

How does the global market for ceftriaxone evolve?

Market structure

Ceftriaxone is widely genericized. That shifts market dynamics from “brand differentiation” to:

• Tender-driven hospital procurement
• Cost per dose and supply reliability
• Regulatory compliance across sourcing geographies
• Form factor preferences (powder for reconstitution versus ready-to-use formats where available)

Demand drivers

The main demand drivers are infection incidence in hospital and outpatient settings and the role of ceftriaxone in empiric therapy pathways:

• Hospital-acquired and community-acquired bacterial infections where third-generation cephalosporins remain first-line or comparator therapy.
• Broader public health use where essential-medicine procurement favors dependable, widely available generics.
• Pediatric usage where dosing guidance and administration practicality influence uptake.

Supply and pricing behavior

Generic antibiotics often exhibit:

• Price compression as supply expands.
• Margin volatility tied to raw-material costs, manufacturing capacity, and procurement cycles.
• Demand resilience because ceftriaxone is entrenched in standard infection protocols.

What is the competitive landscape?

Ceftriaxone’s competitive set is primarily:

• Generic manufacturers supplying hospital markets under national and regional tenders.
• Authorized suppliers where local regulatory pathways and procurement frameworks favor registered products.

Competitive axes that influence winning bids

• Availability and lead time (contract penalties and stock-outs)
• Dose-form stability and handling reliability
• Regulatory status (facility inspections, pharmacovigilance compliance)
• Tender compliance (pack size, labeling language, and distribution terms)

What is the addressable opportunity by product type?

1) Standard ceftriaxone generics

• Highest volume, lowest differentiation.
• Pricing depends on scale and procurement leverage.

2) Lifecycle extensions

• Pediatric-oriented labeling improvements where they translate to clinician confidence.
• Reconstitution and administration convenience improvements.
• Packaging and stability improvements that reduce wastage and support hospital workflow.

3) Alternative presentations

• Ready-to-use or optimized reconstitution solutions where policy and procurement budgets allow.
• Administration regimens optimized for faster workflow or reduced errors.

Clinical-trial update: what to expect next?

Across antibiotics like ceftriaxone, the typical near-term pipeline activity tends to concentrate in:

• Comparative safety/PK studies for pediatric or special populations.
• Formulation work that reduces handling burden and supports hospital inventory management.
• Post-authorization studies aligned with label updates.

In practice, these studies support incremental approvals and label refinements rather than transformative clinical positioning. That matters for investors because it implies:

• Faster timelines to incremental regulatory milestones
• Lower probability of premium pricing unless a product addresses a clear administration or workflow advantage

Market projection for ceftriaxone (base-case, 3 scenarios)

A robust forward-looking forecast for ceftriaxone requires current year revenue and volume baselines, and those are not provided here. Without those inputs, only directionally structured projections can be made based on known market mechanics for established, widely genericized antibiotics: price pressure plus stable demand.

Scenario table: directional outcomes

Scenario	Competitive supply	Price trend	Volume trend	Net market direction
Base case	Normal	Gradual declines offset by mix	Stable	Flat-to-slightly down revenue, stable unit demand
Supply tightening	Capacity constraints, shortages, quality actions	Price lift then normalization	Mild volatility	Revenue up short-term; unit stabilization later
Intensified competition	More low-cost entrants, aggressive tenders	Steeper compression	Stable-to-slight up	Revenue down; unit demand holds

What drives the sign of revenue vs volume

• Revenue follows tender pricing and product mix.
• Volume follows infection incidence and guideline persistence.
• Because ceftriaxone is entrenched and generic, revenue usually moves more than volume.

Regulatory and guideline dependence

Ceftriaxone’s market stability is tied to:

• Guideline inclusion in empiric and targeted therapy pathways for bacterial infections.
• Label applicability to key prescriber populations, especially pediatrics.
• Safety monitoring requirements that hospitals already operationalize.

Where guidelines shift toward other cephalosporins or beta-lactam/beta-lactamase inhibitor combinations, ceftriaxone volumes can soften. Where stewardship favors narrower agents, usage can also shift by infection subtype.

Investment and R&D implications

If your goal is new entry

• Compete on supply reliability, tender compliance, and administration workflow.
• Clinical differentiation must show pragmatic advantages, not just clinical equivalence.

If your goal is lifecycle extension

• Prioritize pediatric- and administration-focused claims that reduce dosing error risk and increase ease of use for nursing workflows.
• Target incremental regulatory value where it supports formulary uptake.

If your goal is manufacturing capacity

• The main risk is procurement price compression plus supply chain disruptions.
• The main lever is scale, quality systems, and stable production runs to avoid tender disqualification.

Key Takeaways

• Ceftriaxone’s clinical development is largely incremental: pediatric dosing, formulation and administration workflow, PK and safety support rather than new mechanism-defining efficacy.
• The market is genericized and tender-driven, so commercial outcome is driven by cost per dose, supply reliability, and regulatory compliance.
• Near-term market direction is typically price pressure with stable demand; revenue tends to track pricing cycles more than infection incidence.
• The most viable R&D routes are lifecycle extensions and formulation/presentation advantages that reduce handling burden or improve pediatric usability.

FAQs

1) Are new efficacy trials likely to change ceftriaxone’s market position?
Usually not. Ceftriaxone’s efficacy is established; trial activity tends to reinforce label utility and comparisons.

2) What patient population attracts the most development work?
Pediatrics, particularly dosing optimization and practical administration in neonates and infants.

3) What determines formulary inclusion more: clinical outcomes or logistics?
Both matter, but for genericized antibiotics, procurement logistics and tender economics often determine adoption pace.

4) How should forecasts treat revenue versus volume?
Expect revenue to be more sensitive to tender pricing and mix, while unit volume is steadier because usage is guideline-driven.

5) Where does differentiation most often come from?
From formulation convenience, administration handling, and label-focused usability improvements rather than new antibacterial spectrum claims.

---

References

[1] World Health Organization. WHO Model List of Essential Medicines. (Most recent edition available online).
[2] U.S. Food and Drug Administration. Drug Development and Drug Approval: Antibiotic-related guidance and labeling resources (relevant general resources).
[3] European Medicines Agency. Ceftriaxone-related assessment documents and product information access portals (relevant general resources).
[4] Centers for Disease Control and Prevention. Antibiotic Use and Stewardship resources (guideline context for use patterns).
[5] Infectious Diseases Society of America and partner guideline groups. Guidelines for management of bacterial infections and empiric therapy recommendations (guideline context).